In another example, intravenous injection of Siltuximab or CNTO 328, which is a chimeric monoclonal antibody binding to IL-6, led to a decrease in the C-reactive protein measure in all SARS-CoV-2-infected cases and, importantly, improved clinical situations by decreasing the requirement for ventilation in 33 percent of COVID-19 cases [73]. The gene discussed is IL6; the disease is COVID-19.